Literature DB >> 20725905

The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation.

Jin-Ping Lai1, Abdul M Oseini, Catherine D Moser, Chunrong Yu, Sherine F Elsawa, Chunling Hu, Ikuo Nakamura, Tao Han, Ileana Aderca, Hajime Isomoto, Megan M Garrity-Park, Abdirashid M Shire, Jia Li, Schuyler O Sanderson, Alex A Adjei, Martin E Fernandez-Zapico, Lewis R Roberts.   

Abstract

UNLABELLED: Heparan sulfate proteoglycans (HSPGs) act as coreceptors or storage sites for growth factors and cytokines such as fibroblast growth factor and Wnts. Glypican 3 (GPC3) is the most highly expressed HSPG in hepatocellular carcinoma (HCC). Sulfatase 2 (SULF2), an enzyme with 6-O-desulfatase activity on HSPGs, is up-regulated in 60% of primary HCCs and is associated with a worse prognosis. We have previously shown that the oncogenic effect of SULF2 in HCC may be mediated in part through up-regulation of GPC3. Here we demonstrate that GPC3 stimulates the Wnt/β-catenin pathway and mediates the oncogenic function of SULF2 in HCC. Wnt signaling in vitro and in vivo was assessed in SULF2-negative Hep3B HCC cells transfected with SULF2 and in SULF2-expressing Huh7 cells transfected with short hairpin RNA targeting SULF2. The interaction between GPC3, SULF2, and Wnt3a was assessed by coimmunoprecipitation and flow cytometry. β-catenin-dependent transcriptional activity was assessed with the TOPFLASH (T cell factor reporter plasmid) luciferase assay. In HCC cells, SULF2 increased cell surface GPC3 and Wnt3a expression, stabilized β-catenin, and activated T cell factor transcription factor activity and expression of the Wnt/β-catenin target gene cyclin D1. Opposite effects were observed in SULF2-knockdown models. In vivo, nude mouse xenografts established from SULF2-transfected Hep3B cells showed enhanced GPC3, Wnt3a, and β-catenin levels.
CONCLUSION: Together, these findings identify a novel mechanism mediating the oncogenic function of SULF2 in HCC that includes GPC3-mediated activation of Wnt signaling via the Wnt3a/glycogen synthase kinase 3 beta axis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20725905      PMCID: PMC2967616          DOI: 10.1002/hep.23848

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  22 in total

1.  Overexpression of beta-catenin induces apoptosis independent of its transactivation function with LEF-1 or the involvement of major G1 cell cycle regulators.

Authors:  K Kim; K M Pang; M Evans; E D Hay
Journal:  Mol Biol Cell       Date:  2000-10       Impact factor: 4.138

2.  Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders.

Authors:  Z W Zhu; H Friess; L Wang; M Abou-Shady; A Zimmermann; A D Lander; M Korc; J Kleeff; M W Büchler
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

3.  SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.

Authors:  Jin-Ping Lai; Chunrong Yu; Catherine D Moser; Ileana Aderca; Tao Han; Thomas D Garvey; Linda M Murphy; Megan M Garrity-Park; Viji Shridhar; Alex A Adjei; Lewis R Roberts
Journal:  Gastroenterology       Date:  2006-06       Impact factor: 22.682

Review 4.  Heparin-degrading sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets.

Authors:  Jin-Ping Lai; James R Thompson; Dalbir S Sandhu; Lewis R Roberts
Journal:  Future Oncol       Date:  2008-12       Impact factor: 3.404

Review 5.  The tumor suppressor function of human sulfatase 1 (SULF1) in carcinogenesis.

Authors:  Jin-Ping Lai; Dalbir S Sandhu; Abdirashid M Shire; Lewis R Roberts
Journal:  J Gastrointest Cancer       Date:  2009-04-17

6.  Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo.

Authors:  Sandra I Zittermann; Mariana I Capurro; Wen Shi; Jorge Filmus
Journal:  Int J Cancer       Date:  2010-03-15       Impact factor: 7.396

7.  Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma.

Authors:  Jin-Ping Lai; Dalbir S Sandhu; Chunrong Yu; Tao Han; Catherine D Moser; Kenard K Jackson; Ruben Bonilla Guerrero; Ileana Aderca; Hajime Isomoto; Megan M Garrity-Park; Hongzhi Zou; Abdirashid M Shire; David M Nagorney; Schuyler O Sanderson; Alex A Adjei; Ju-Seog Lee; Snorri S Thorgeirsson; Lewis R Roberts
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

8.  Heparan sulfate proteoglycans are critical for the organization of the extracellular distribution of Wingless.

Authors:  G H Baeg; X Lin; N Khare; S Baumgartner; N Perrimon
Journal:  Development       Date:  2001-01       Impact factor: 6.868

9.  Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis.

Authors:  H Lemjabbar-Alaoui; A van Zante; M S Singer; Q Xue; Y-Q Wang; D Tsay; B He; D M Jablons; S D Rosen
Journal:  Oncogene       Date:  2009-10-26       Impact factor: 9.867

10.  Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma.

Authors:  A Bengochea; M M de Souza; L Lefrançois; E Le Roux; O Galy; I Chemin; M Kim; J R Wands; C Trepo; P Hainaut; J-Y Scoazec; L Vitvitski; P Merle
Journal:  Br J Cancer       Date:  2008-06-24       Impact factor: 7.640

View more
  56 in total

1.  A Frizzled-Like Cysteine-Rich Domain in Glypican-3 Mediates Wnt Binding and Regulates Hepatocellular Carcinoma Tumor Growth in Mice.

Authors:  Na Li; Liwen Wei; Xiaoyu Liu; Hongjun Bai; Yvonne Ye; Dan Li; Nan Li; Ulrich Baxa; Qun Wang; Ling Lv; Yun Chen; Mingqian Feng; Byungkook Lee; Wei Gao; Mitchell Ho
Journal:  Hepatology       Date:  2019-05-24       Impact factor: 17.425

Review 2.  Glycosylation alterations in lung and brain cancer.

Authors:  Hassan Lemjabbar-Alaoui; Andrew McKinney; Yi-Wei Yang; Vy M Tran; Joanna J Phillips
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

3.  Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors.

Authors:  Jin-Ping Lai; Dalbir S Sandhu; Chunrong Yu; Catherine D Moser; Chunling Hu; Abdirashid M Shire; Ileana Aderca; Linda M Murphy; Alex A Adjei; Schuyler Sanderson; Lewis R Roberts
Journal:  Liver Int       Date:  2010-09-08       Impact factor: 5.828

4.  The extracellular sulfatase SULF2 promotes liver tumorigenesis by stimulating assembly of a promoter-looping GLI1-STAT3 transcriptional complex.

Authors:  Ryan M Carr; Paola A Romecin Duran; Ezequiel J Tolosa; Chenchao Ma; Abdul M Oseini; Catherine D Moser; Bubu A Banini; Jianbo Huang; Faizal Asumda; Renumathy Dhanasekaran; Rondell P Graham; Merih D Toruner; Stephanie L Safgren; Luciana L Almada; Shaoqing Wang; Mrinal M Patnaik; Lewis R Roberts; Martin E Fernandez-Zapico
Journal:  J Biol Chem       Date:  2020-01-27       Impact factor: 5.157

5.  Overexpression of HLA-DR is associated with prognosis of glioma patients.

Authors:  Jinfu Diao; Tianbao Xia; Hongwei Zhao; Jialin Liu; Bin Li; Zhiwen Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

6.  Hypoxia negatively regulates heparan sulfatase 2 expression in renal cancer cell lines.

Authors:  Ashwani Khurana; Han W Tun; Laura Marlow; John A Copland; Keith Dredge; Viji Shridhar
Journal:  Mol Carcinog       Date:  2011-07-07       Impact factor: 4.784

7.  Expression profile of altered long non-coding RNAs in patients with HBV-associated hepatocellular carcinoma.

Authors:  Yan-Feng Pan; Tao Qin; Lei Feng; Zu-Jiang Yu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-02-08

Review 8.  Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.

Authors:  Yukihiro Haruyama; Hiroaki Kataoka
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 9.  Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin.

Authors:  Mitchell Ho
Journal:  BioDrugs       Date:  2011-10-01       Impact factor: 5.807

10.  MicroRNA-422a functions as a tumor suppressor in non-small cell lung cancer through SULF2-mediated TGF-β/SMAD signaling pathway.

Authors:  Wei-Qiang Li; Jian-Peng Zhang; Yan-Yu Wang; Xin-Zhen Li; Lin Sun
Journal:  Cell Cycle       Date:  2019-06-28       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.